Periodic Screening Not Routinely Recommended for Family History Alone
In this 63-year-old woman with normal screening labs (CBC, CMP, SPEP), routine periodic re-evaluation is not indicated based solely on family history of multiple myeloma, as family history is not an established risk factor for progression in the absence of a detectable monoclonal protein.
Key Clinical Context
Multiple myeloma does not have well-established familial inheritance patterns that warrant routine screening in asymptomatic individuals. The guidelines focus on monitoring patients who already have detectable monoclonal proteins (MGUS or smoldering myeloma), not on screening healthy individuals with family history 1, 2, 3.
What Your Patient Actually Has
Since your patient has:
- Normal SPEP (no monoclonal protein detected)
- Normal CBC and CMP
- No evidence of MGUS or smoldering myeloma
She does not meet criteria for any plasma cell disorder requiring monitoring 1, 2.
Evidence-Based Approach
Why Routine Monitoring Is Not Indicated
- MGUS progression risk is 1% per year and requires the presence of a detectable monoclonal protein to even diagnose 1, 2
- Guidelines recommend monitoring only for patients with documented MGUS or smoldering myeloma, not for screening asymptomatic individuals 3, 4
- The International Myeloma Working Group consensus does not identify family history as a criterion for surveillance 5
What Should Trigger Re-evaluation
Repeat testing is only warranted if she develops:
- Unexplained anemia (hemoglobin <10 g/dL or ≥2 g/dL below normal) 1, 2
- Renal insufficiency (creatinine >2 mg/dL or clearance <40 mL/min) 1, 2
- Hypercalcemia (calcium >11.5 mg/dL) 1, 2
- Bone pain or pathologic fractures 1, 2
- Unexplained fatigue, weight loss, or recurrent infections 3
- Proteinuria on routine urinalysis 3
Clinical Recommendation
Counsel the patient to:
- Report any new symptoms listed above promptly
- Ensure routine age-appropriate health maintenance continues (which includes CBC and CMP periodically for other reasons)
- Understand that if a monoclonal protein is detected incidentally in the future, then risk-stratified monitoring would begin
Do not order routine SPEP or other myeloma-specific screening in the absence of clinical indicators 3, 4.
Important Caveat
If this patient had an IgA or IgM monoclonal protein (even if small), bone marrow examination would be recommended regardless of protein size, as these carry higher risk 4. However, since SPEP is normal, this does not apply.
The recent 2025 review emphasizes that testing for monoclonal proteins should be reserved for when malignant disease is actually suspected, not for routine screening, as previous disease associations were likely overestimated in screened populations 6.